Behandlung des duktalen Carcinoma in situ

Translated title of the contribution: Treatment of ductal carcinoma in situ

M. Thill*, S. Kapsimalakou, K. Diedrich, K. Baumann

*Corresponding author for this work


Ductal carcinoma in situ (DCIS) as a non-invasive carcinoma is a precancerous lesion of the breast. The increased use of mammography during the last three decades has led to an approximately tenfold higher incidence of this lesion. The fundamental question underlying treatment and detection of DCIS is whether it should be considered a direct precursor of invasive breast cancer. This reflects our therapeutic dilemma. Current management strategies range from mastectomy to excision plus radiation therapy to excision alone. There is a lack of predictive and prognostic markers and is limited to surrogate markers of clinical behaviour. Expression of oestrogen receptor (ER) is the precondition for endocrine treatment, but nevertheless tamoxifen therapy is not recommended generally. Different studies on the value of HER2 overexpression are ongoing but do not influence our therapy. To date, there has been no subgroup identified where radiation therapy after breast-conserving surgery can be avoided.

Translated title of the contributionTreatment of ductal carcinoma in situ
Original languageGerman
Issue number4
Pages (from-to)269-275
Number of pages7
Publication statusPublished - 01.04.2012


Dive into the research topics of 'Treatment of ductal carcinoma in situ'. Together they form a unique fingerprint.

Cite this